Sapropterin treatment does not enhance the health‐related quality of life of patients with phenylketonuria and their parents

Sapropterin causes reductions in blood phenylalanine concentrations in sensitive patients with phenylketonuria (PKU). We examined whether the subsequent relaxation of dietary restrictions influenced the quality of life (QoL) of patients and parents.

[1]  Luis A. M. Barros,et al.  Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping review , 2018, Orphanet Journal of Rare Diseases.

[2]  A. Harthan.  An Introduction to Pharmacotherapy for Inborn Errors of Metabolism. , 2018, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[3]  Rani H. Singh,et al.  Caregiver Quality of Life with Tyrosinemia Type 1 , 2018, Journal of Genetic Counseling.

[4]  E. Bettiol,et al.  Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries , 2015, Orphanet Journal of Rare Diseases.

[5]  N. Blau,et al.  Long-term Follow-up and Outcome of Phenylketonuria Patients on Sapropterin: A Retrospective Study , 2013, Pediatrics.

[6]  L. Goldbeck,et al.  Quality of life among parents of children with phenylketonuria (PKU) , 2013, Health and Quality of Life Outcomes.

[7]  U. Ceglarek,et al.  Tetrahydrobiopterin (BH4) in PKU: effect on dietary treatment, metabolic control, and quality of life , 2012, Journal of Inherited Metabolic Disease.

[8]  H. Maurice‐Stam,et al.  Parenting a child with phenylketonuria or galactosemia: implications for health-related quality of life , 2011, Journal of Inherited Metabolic Disease.

[9]  G. Enns,et al.  Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. , 2010, Molecular genetics and metabolism.

[10]  S. Gersting,et al.  Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. , 2010, Human molecular genetics.

[11]  J. Vockley,et al.  Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. , 2009, The Journal of pediatrics.

[12]  N. Blau,et al.  Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. , 2009, Molecular genetics and metabolism.

[13]  Gert B. M. Mensink,et al.  The challenge of comprehensively mapping children's health in a nation-wide health survey: Design of the German KiGGS-Study , 2008, BMC public health.

[14]  A. Chakrapani,et al.  Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study , 2007, The Lancet.

[15]  N. Blau,et al.  Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. , 2005, Molecular genetics and metabolism.

[16]  Aurora Martínez,et al.  Tetrahydrobiopterin protects phenylalanine hydroxylase activity in vivo: Implications for tetrahydrobiopterin‐responsive hyperphenylalaninemia , 2004, FEBS letters.

[17]  A. Roscher,et al.  Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. , 2002, The New England journal of medicine.

[18]  A. Macdonald.  Diet and compliance in phenylketonuria , 2000, European Journal of Pediatrics.

[19]  S. Kure,et al.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. , 1999, The Journal of pediatrics.

[20]  M. Bullinger,et al.  Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results , 1998, Quality of Life Research.

[21]  E. Treacy,et al.  Extended Experience of Lower Dose Sapropterin in Irish Adults with Mild Phenylketonuria. , 2018, JIMD reports.

[22]  T. Marquardt,et al.  Influence of PAH Genotype on Sapropterin Response in PKU: Results of a Single-Center Cohort Study. , 2014, JIMD reports.

[23]  H. Maurice‐Stam,et al.  Evaluation of quality of life in PKU before and after introducing tetrahydrobiopterin (BH4); a prospective multi-center cohort study. , 2013, Molecular genetics and metabolism.

[24]  C. Harding,et al.  Up to date knowledge on different treatment strategies for phenylketonuria. , 2011, Molecular genetics and metabolism.

[25]  L. Goldbeck,et al.  Das Ulmer Lebensqualitäts-Inventar für Eltern chronisch kranker Kinder (ULQIE): , 2002 .

[26]  H. Bremer,et al.  Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997 , 1999, European Journal of Pediatrics.